Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Biophytis SA (FP: ALBPS) has announced its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), scheduled for March 12-14 in Toulouse. This prestigious annual scientific event focuses on advancing clinical trials for frail older adults and brings together researchers, clinicians, and industry professionals.
During a special session on obesity-associated sarcopenia, Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101. This treatment aims to preserve muscle and mobility in patients with obesity who are being treated with GLP-1 receptor agonists.
The ICFSR is known for its rigorous peer-review process, with all presented research being reviewed by the ICFSR Scientific Committee and published in the Journal of Frailty and Aging (JFA), a peer-reviewed publication specializing in aging and age-related diseases.
Biophytis SA (FP: ALBPS) ha annunciato la sua partecipazione alla Conferenza Internazionale sulla Fragilità e Sarcopenia e Task Force di Geroscienza (ICFSR), in programma dal 12 al 14 marzo a Tolosa. Questo prestigioso evento scientifico annuale si concentra sul progresso dei trial clinici per gli anziani fragili e riunisce ricercatori, clinici e professionisti del settore.
Durante una sessione speciale sulla sarcopenia associata all'obesità, Biophytis presenterà le motivazioni e i dati preliminari a sostegno dello sviluppo clinico di BIO101. Questo trattamento mira a preservare la massa muscolare e la mobilità nei pazienti obesi che vengono trattati con agonisti del recettore GLP-1.
L'ICFSR è conosciuta per il suo rigoroso processo di revisione tra pari, con tutta la ricerca presentata che viene esaminata dal Comitato Scientifico dell'ICFSR e pubblicata nel Journal of Frailty and Aging (JFA), una pubblicazione sottoposta a revisione tra pari specializzata nell'invecchiamento e nelle malattie correlate all'età.
Biophytis SA (FP: ALBPS) ha anunciado su participación en la Conferencia Internacional sobre Fragilidad e Investigación en Sarcopenia y Grupo de Trabajo de Gerociencia (ICFSR), programada del 12 al 14 de marzo en Toulouse. Este prestigioso evento científico anual se centra en el avance de ensayos clínicos para adultos mayores frágiles y reúne a investigadores, clínicos y profesionales de la industria.
Durante una sesión especial sobre sarcopenia asociada a la obesidad, Biophytis presentará la justificación y los datos preliminares que respaldan el desarrollo clínico de BIO101. Este tratamiento tiene como objetivo preservar la masa muscular y la movilidad en pacientes con obesidad que están siendo tratados con agonistas del receptor GLP-1.
El ICFSR es conocido por su riguroso proceso de revisión por pares, con toda la investigación presentada revisada por el Comité Científico del ICFSR y publicada en el Journal of Frailty and Aging (JFA), una publicación revisada por pares especializada en el envejecimiento y enfermedades relacionadas con la edad.
Biophytis SA (FP: ALBPS)는 국제 노인 약화 및 근감소증 연구 회의 및 노화 과학 태스크 포스 (ICFSR)에 참여한다고 발표했습니다. 이 회의는 3월 12일부터 14일까지 툴루즈에서 열릴 예정이며, 노인 환자의 임상 시험을 발전시키는 데 중점을 두고 연구자, 임상 의사 및 산업 전문가들이 모입니다.
비만 관련 근감소증에 대한 특별 세션에서 Biophytis는 BIO101의 임상 개발을 뒷받침하는 근거와 초기 데이터를 발표할 예정입니다. 이 치료법은 GLP-1 수용체 작용제로 치료받고 있는 비만 환자의 근육과 이동성을 보존하는 것을 목표로 합니다.
ICFSR는 엄격한 동료 검토 과정으로 잘 알려져 있으며, 발표된 모든 연구는 ICFSR 과학 위원회에 의해 검토되고 Journal of Frailty and Aging (JFA)에 발표됩니다. 이 저널은 노화 및 노화 관련 질병을 전문으로 하는 동료 검토 저널입니다.
Biophytis SA (FP: ALBPS) a annoncé sa participation à la Conférence Internationale sur la Fragilité et la Recherche en Sarcopénie & Task Force de Gérontologie (ICFSR), prévue du 12 au 14 mars à Toulouse. Cet événement scientifique annuel prestigieux se concentre sur l'avancement des essais cliniques pour les personnes âgées fragiles et réunit des chercheurs, des cliniciens et des professionnels de l'industrie.
Lors d'une session spéciale sur la sarcopénie associée à l'obésité, Biophytis présentera les raisons et les données préliminaires soutenant le développement clinique de BIO101. Ce traitement vise à préserver la masse musculaire et la mobilité chez les patients obèses traités par des agonistes des récepteurs GLP-1.
L'ICFSR est connue pour son processus de révision par les pairs rigoureux, toutes les recherches présentées étant examinées par le Comité Scientifique de l'ICFSR et publiées dans le Journal of Frailty and Aging (JFA), une publication évaluée par des pairs spécialisée dans le vieillissement et les maladies liées à l'âge.
Biophytis SA (FP: ALBPS) hat seine Teilnahme an der Internationalen Konferenz über Fragilität und Sarkopenie-Forschung & Geroscience Task Force (ICFSR) angekündigt, die vom 12. bis 14. März in Toulouse stattfinden wird. Diese prestigeträchtige jährliche wissenschaftliche Veranstaltung konzentriert sich auf die Weiterentwicklung klinischer Studien für fragile ältere Erwachsene und bringt Forscher, Kliniker und Fachleute aus der Industrie zusammen.
Während einer speziellen Sitzung zur obesitätsassoziierten Sarkopenie wird Biophytis die Gründe und vorläufigen Daten präsentieren, die die klinische Entwicklung von BIO101 unterstützen. Diese Behandlung zielt darauf ab, die Muskulatur und Mobilität bei adipösen Patienten zu erhalten, die mit GLP-1-Rezeptoragonisten behandelt werden.
Die ICFSR ist bekannt für ihren strengen Peer-Review-Prozess, wobei alle präsentierten Forschungsarbeiten vom Wissenschaftlichen Komitee der ICFSR überprüft und im Journal of Frailty and Aging (JFA) veröffentlicht werden, einer peer-reviewed Publikation, die sich auf das Alter und altersbedingte Krankheiten spezialisiert hat.
- Biophytis will present preliminary data on BIO101 for obesity-associated sarcopenia
- Participation in prestigious ICFSR conference provides scientific visibility
- Research targeting patients on GLP-1 receptor agonists addresses growing market
- None.
Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the International Conference on Frailty and Sarcopenia Research & Geroscience Task Force (ICFSR), taking place from March 12 to 14 in Toulouse.
The International Conference on Frailty and Sarcopenia Research (ICFSR) is a leading annual scientific event dedicated to accelerating the development of clinical trials for frail older adults. It brings together researchers, clinicians, and industry professionals to share their experiences and advances in the prevention of frailty, disability, and dependency. All presented research undergoes a rigorous peer-review process by the ICFSR Scientific Committee and are published in the Journal of Frailty and Aging (JFA), a peer-reviewed journal specialized in aging and age-related diseases.
As part of a special session on obesity-associated sarcopenia, Biophytis will present the rationale and preliminary data supporting the clinical development of BIO101 in the preservation of muscle and mobility of patients suffering from obesity treated with GLP-1 receptor agonists.
* * * *
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Contacts Biophytis
Relations Investisseurs
Investors@biophytis.com
US Investors
Pascal Nigen - Alpha Bronze
pnigen@alphabronzellc.com
Media contacts
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242167
FAQ
What will Biophytis (ALBPS) present at the ICFSR conference in March 2025?
When and where is the 15th International Conference on Frailty and Sarcopenia Research that Biophytis (ALBPS) is attending?
What is BIO101 being developed for by Biophytis (ALBPS)?
How might Biophytis' (ALBPS) participation in the ICFSR conference impact its research visibility?
What is the significance of Biophytis (ALBPS) targeting obesity patients on GLP-1 receptor agonists?
